Suppr超能文献

循环疫苗衍生脊髓灰质炎病毒:当前的知识状况

Circulating vaccine-derived polioviruses: current state of knowledge.

作者信息

Kew Olen M, Wright Peter F, Agol Vadim I, Delpeyroux Francis, Shimizu Hiroyuki, Nathanson Neal, Pallansch Mark A

机构信息

WHO Global Specialized Reference Laboratory, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.

出版信息

Bull World Health Organ. 2004 Jan;82(1):16-23. Epub 2004 Feb 26.

Abstract

Within the past 4 years, poliomyelitis outbreaks associated with circulating vaccine-derived polioviruses (cVDPVs) have occurred in Hispaniola (2000-01), the Philippines (2001), and Madagascar (2001-02). Retrospective studies have also detected the circulation of endemic cVDPV in Egypt (1988-93) and the likely localized spread of oral poliovirus vaccine (OPV)-derived virus in Belarus (1965-66). Gaps in OPV coverage and the previous eradication of the corresponding serotype of indigenous wild poliovirus were the critical risk factors for all cVDPV outbreaks. The cVDPV outbreaks were stopped by mass immunization campaigns using OPV. To increase sensitivity for detecting vaccine-derived polioviruses (VDPVs), in 2001 the Global Polio Laboratory Network implemented additional testing requirements for all poliovirus isolates under investigation. This approach quickly led to the recognition of the Philippines and Madagascar cVDPV outbreaks, but of no other current outbreaks. The potential risk of cVDPV emergence has increased dramatically in recent years as wild poliovirus circulation has ceased in most of the world. The risk appears highest for the type 2 OPV strain because of its greater tendency to spread to contacts. The emergence of cVDPVs underscores the critical importance of eliminating the last pockets of wild poliovirus circulation, maintaining universally high levels of polio vaccine coverage, stopping OPV use as soon as it is safely possible to do so, and continuing sensitive poliovirus surveillance into the foreseeable future. Particular attention must be given to areas where the risks for wild poliovirus circulation have been highest, and where the highest rates of polio vaccine coverage must be maintained to suppress cVDPV emergence.

摘要

在过去4年中,与疫苗衍生脊髓灰质炎病毒(cVDPV)传播相关的脊髓灰质炎疫情在伊斯帕尼奥拉岛(2000 - 2001年)、菲律宾(2001年)和马达加斯加(2001 - 2002年)爆发。回顾性研究还在埃及(1988 - 1993年)检测到地方性cVDPV的传播,并在白俄罗斯(1965 - 1966年)发现口服脊髓灰质炎疫苗(OPV)衍生病毒可能存在局部传播。OPV覆盖率的差距以及先前对相应血清型本土野生脊髓灰质炎病毒的根除是所有cVDPV疫情爆发的关键风险因素。通过使用OPV的大规模免疫运动,cVDPV疫情得以遏制。为提高检测疫苗衍生脊髓灰质炎病毒(VDPV)的敏感性,全球脊髓灰质炎实验室网络于2001年对所有正在调查的脊髓灰质炎病毒分离株实施了额外检测要求。这种方法很快促使人们认识到菲律宾和马达加斯加的cVDPV疫情,但未发现其他当前疫情。近年来,随着世界上大多数地区野生脊髓灰质炎病毒传播的停止,cVDPV出现的潜在风险急剧增加。由于2型OPV毒株更容易传播给接触者,其风险似乎最高。cVDPV的出现凸显了消除野生脊髓灰质炎病毒传播的最后据点、维持普遍高水平的脊髓灰质炎疫苗覆盖率、一旦安全可行就尽快停止使用OPV以及在可预见的未来持续进行敏感的脊髓灰质炎病毒监测的至关重要性。必须特别关注野生脊髓灰质炎病毒传播风险最高以及必须维持最高脊髓灰质炎疫苗覆盖率以抑制cVDPV出现的地区。

相似文献

1
Circulating vaccine-derived polioviruses: current state of knowledge.
Bull World Health Organ. 2004 Jan;82(1):16-23. Epub 2004 Feb 26.
2
Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.
MMWR Morb Mortal Wkly Rep. 2011 Jul 1;60(25):846-50.
3
Update on vaccine-derived polioviruses.
MMWR Morb Mortal Wkly Rep. 2006 Oct 13;55(40):1093-7.
4
A developing country perspective on vaccine-associated paralytic poliomyelitis.
Bull World Health Organ. 2004 Jan;82(1):53-7; discussion 57-8. Epub 2004 Feb 26.
5
Update on vaccine-derived polioviruses--worldwide, April 2011-June 2012.
MMWR Morb Mortal Wkly Rep. 2012 Sep 21;61:741-6.
6
Update on vaccine-derived polioviruses--worldwide, January 2008-June 2009.
MMWR Morb Mortal Wkly Rep. 2009 Sep 18;58(36):1002-6.
7
Update on Vaccine-Derived Polioviruses - Worldwide, January 2016-June 2017.
MMWR Morb Mortal Wkly Rep. 2017 Nov 3;66(43):1185-1191. doi: 10.15585/mmwr.mm6643a6.
8
Estimating the extent of vaccine-derived poliovirus infection.
PLoS One. 2008;3(10):e3433. doi: 10.1371/journal.pone.0003433. Epub 2008 Oct 29.
10
Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.
MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):640-6.

引用本文的文献

3
A highly immunogenic UVC inactivated Sabin based polio vaccine.
NPJ Vaccines. 2024 Nov 14;9(1):217. doi: 10.1038/s41541-024-00995-w.
4
Monitoring the evolution of vaccine-derived poliovirus in East and Southern African countries, 2010 - 2021.
Pan Afr Med J. 2024 Jan 25;47:31. doi: 10.11604/pamj.2024.47.31.39945. eCollection 2024.
6
Genetic characterization and molecular evolution of type 3 vaccine-derived polioviruses from an immunodeficient patient in China.
Virus Res. 2023 Sep;334:199177. doi: 10.1016/j.virusres.2023.199177. Epub 2023 Jul 24.
7
Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human.
Virol J. 2022 Dec 8;19(1):209. doi: 10.1186/s12985-022-01945-5.
8
Curbing an outbreak of circulating vaccine derived poliovirus type 2 in Dollo Zone, Somali Region, Ethiopia: response to outbreak.
Pan Afr Med J. 2022 May 17;42:46. doi: 10.11604/pamj.2022.42.46.32856. eCollection 2022.
9
[Discovery of Foci of Type-2 Poliovirus Derived from Oral Polio Vaccine in Central African Republic in 2019].
Med Trop Sante Int. 2021 Jun 20;1(2). doi: 10.48327/mtsibulletin.2021.114. eCollection 2021 Jun 30.
10
Circulating vaccine derived polio virus type 1 outbreak, Saadah governorate, Yemen, 2020.
BMC Infect Dis. 2022 Apr 29;22(1):414. doi: 10.1186/s12879-022-07397-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验